Caladrius Biosciences Inc

NASDAQ:CLBS   3:59:46 PM EDT
1.51
0.00 (0.00%)
Products, Regulatory

Caladrius Biosciences Says COVID-19 Most Negatively Impacted Registration-Eligible Trial In Japan Of Sakigake-Designated Product, Honedra

Published: 12/14/2020 13:18 GMT
Caladrius Biosciences Inc (CLBS) - Caladrius Biosciences - Covid-19 Most Negatively Impacted Registration-eligible Trial in Japan of Sakigake-designated Product, Honedra.
Caladrius Biosciences Inc - Honedra Could Have an Approval Decision in Japan As Early As Late 2022 Or Early 2023.
Caladrius Biosciences - Phase 2b Freedom Trial for Clbs16 Targeted to Complete Enrollment by End of 2021; Hope to Have Top-line Data in Q3 2022.
Caladrius Biosciences Inc - Hope to Obtain Clarity on Development Plan for Clbs14 During First Half of 2021.